BioSpace News Archive

ViewRay, Inc. announced that the company’s MRIdian MRI-Guided Radiation Therapy System has received approval from the Chinese regulatory authority National Medical Products Administration, allowing for its sale and utilization throughout China.

Nuvalent, Inc. announced it will present preliminary dose escalation data from its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors during an oral plenary session at the 34th EORTC-NCI-AACR Symposium taking place October 26-28, 2022 in Barcelona, Spain.

Rebranding aligns core Biosynth Group members across Complex Chemical and Peptide Manufacturing Services and Catalog Business.

Avivagen Inc. is pleased to announce that its scientific paper entitled “Safety and uptake of fully Oxidized Beta Carotene” has been published in the Journal of Food and Chemical Toxicology.

Orbital Therapeutics launched with a vision of enhancing global health by unleashing the full potential of RNA medicines to treat human disease in ways that were not previously possible.

Pfizer Inc. announced that its investigational Group B Streptococcus vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy.

Arch Therapeutics, Inc. announced that it has launched a multi-site clinical study to accelerate payor adoption and differentiate the key benefits of AC5® Advanced Wound System in treating challenging wounds.

Velocity Clinical Research, the leading integrated research site organization, announces it has acquired MedPharmics, a multi-site company based in the US.

UCB, a global biopharmaceutical company, today announced new three-year results from the BE BRIGHT open-label extension (OLE) study evaluating the long-term safety, tolerability and efficacy of bimekizumab in adults with moderate to severe plaque psoriasis who completed one of three pivotal Phase 3 studies.

FluGen, Inc., today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s investigational supra-seasonal intranasal influenza (flu) vaccine, in volunteers ages 6 months to 17 years old.